secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALLURION TECHNOLOGIES, INC. (ALUR)
CIK:        0001964979
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-104347
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allurion cuts ~65% workforce, reports preliminary Q2 revenue ~$3M, shifts to GLP-1 combo therapy
--------------------------------------------------------------------------------

- Preliminary Q2 2025 revenue ~$3M, operating loss ~$7M, improved from $9.3M loss in Q2 2024; operating expenses down ~50% YoY.
- Restructuring: workforce reduction of ~70 employees (~65% of total); estimated severance charges of ~$1.5M; completion expected by end of Q3 2025.
- Signed term sheet with strategic partner for ex-US distribution and potential joint development of a GLP-1 drug-eluting intragastric balloon.
- Submitted protocol to IRBs for prospective study on low-dose GLP-1 + Allurion Program for weight loss and muscle preservation; enrollment expected in 2025.
- PMA application for Allurion Balloon accepted by FDA for evaluation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1964979/000095017025104347/0000950170-25-104347-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1964979/000095017025104347/alur-20250804.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-104347

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer